Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dynamics and tracer distribution of Tilmanocept using combined subareolar and peritumoral injection technique for scintigraphic sentinel lymph node detection in early stage breast cancer

Next Previous
X
Search
Trial Profile

Dynamics and tracer distribution of Tilmanocept using combined subareolar and peritumoral injection technique for scintigraphic sentinel lymph node detection in early stage breast cancer

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 24 May 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tc 99m tilmanocept (Primary) ; Technetium Tc 99m nanocolloid
  • Indications Early breast cancer
  • Focus Diagnostic use

    • Most Recent Events

    • 22 May 2021 This trial has been completed in Belgium, according to European Clinical Trials Database.
    • 12 May 2021 Planned End Date changed from 1 Sep 2021 to 1 May 2021.
    • 12 May 2021 Planned primary completion date changed from 1 Jul 2021 to 1 May 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top